MBDP, also known as N-methyl-1,3-benzodioxolylpentanamine, 3,4-methylenedioxy-α-propyl-N-methylphenethylamine, methyl-K, or UWA-091, is a psychoactive drug of the phenethylamine, phenylisobutylamine, and MDxx families.[1][2][3] It is the N–methyl analogue of BDP (K).[1]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MBDP’s minimum dose as 100 mg orally and its duration as unknown.[1] The drug produced no effects at tested doses.[1]
Chemistry
Synthesis
The chemical synthesis of MBDP has been described.[1]
Society and culture
Legal status
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[4]
See also
- Substituted methylenedioxyphenethylamine
- Pentylone (bk-MBDP)
- Ethylbenzodioxolylpentanamine (EBDP; Ethyl-K)
- Methylbenzodioxolylbutanamine (MBDB; Methyl-J)
- Methylenedioxyphenylpropylaminopentane (MPAP)
- UWA-101 (α-cyclopropyl-MDPEA)
References
- ^ a b c d e f g “Methyl-K”. PiHKAL.
- ^ Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
- ^ Shulgin AT (2003). “Basic Pharmacology and Effects”. In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
- ^ “UK Misuse of Drugs act 2001 Amendment summary”. Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.